Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 6/20 | 1.00 |
| ▸ | HSD11B2 | P80365 | 5/20 | 1.00 |
| ▸ | HSD11B1 | P28845 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.79 |
| ▸ | LMNA | P02545 | 5/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.79 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | TSHR | P16473 | 3/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.79 |
| ▸ | SHBG | P04278 | 3/20 | 0.79 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.79 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.79 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.79 |
| ▸ | THPO | P40225 | 2/20 | 0.79 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 11Beta-Hydroxyprogesterone SCHEMBL18927076 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL572275 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL14217113 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL985222 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL23131395 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL24900301 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL19327159 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL13753022 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL4895684 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL14039977 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250279209-A1 | PROVISION OF A MEDICAL RISK ASSESSMENT FOR NONCLASSICAL 21-HYDROXYLASE DEFICIENCY | UNIV SORBONNE (FR) | 2025-09-04 | — | — | US | claimed |
| EP-4511660-A1 | PROVISION OF A MEDICAL RISK ASSESSMENT FOR NONCLASSICAL 21-HYDROXYLASE DEFICIENCY | SORBONNE UNIVERSITE (FR) | 2025-02-26 | — | — | EP | claimed |
| CN-117805284-B | Method for simultaneously detecting multiple precocious biomarkers | 裕菁科技(上海)有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-118647367-A | Novel injectable combination formulations | 南爱克萨股份公司 | 2024-09-13 | — | — | CN | claimed |
| CN-118584010-A | Primary aldosteronism steroid hormone model, preparation method and application thereof | 上海交通大学医学院附属瑞金医院 | 2024-09-03 | — | — | CN | claimed |
| CN-117849228-A | Biomarker for screening early sexual precocity and application thereof | 裕菁科技(上海)有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117805284-A | Method for simultaneously detecting multiple precocious biomarkers | 裕菁科技(上海)有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-117030904-B | Method for measuring 144 steroid hormones in environmental sample by liquid chromatography-mass spectrometry | 北京林业大学 | 2023-12-19 | — | — | CN | claimed |
| CN-117030904-A | Method for measuring 144 steroid hormones in environmental sample by liquid chromatography-mass spectrometry | 北京林业大学 | 2023-11-10 | — | — | CN | claimed |
| WO-2023203284-A1 | PROVISION OF A MEDICAL RISK ASSESSMENT FOR NONCLASSICAL 21-HYDROXYLASE DEFICIENCY | SORBONNE UNIVERSITE (FR) | 2023-10-26 | — | — | WO | claimed |
| CN-116448923-A | Methods and kits for extracting and detecting steroid hormones and catecholamine metabolites | 中国医学科学院北京协和医院 | 2023-07-18 | — | — | CN | claimed |
| US-20210386712-A1 | NEW USE OF ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST | VICORE PHARMA AB (SE) | 2021-12-16 | — | — | US | claimed |
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | Spectral Analytics, Inc. (US) | 2021-09-30 | — | — | US | claimed |
| US-10088490-B2 | Assay for analytes using multiple receptors | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2018-10-02 | — | — | US | claimed |
| US-20150376225-A1 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | EPIRIUM BIO INC. | 2015-12-31 | — | — | US | claimed |
| US-20090053294-A1 | Anti Mineralocorticoid Therapy of Infection | PRENDERGAST PATRICK T | 2009-02-26 | — | — | US | claimed |
| EP-0141684-B1 | HYDROCORTISONE-17-CARBOXYLIC-ACID ESTER 21-THIOCARBOXYLYC-ACID ESTERS, THEIR PREPARATION AND THEIR USE AS MEDICINES | JOUVEINAL S.A. (FR) | 1987-09-30 | — | — | EP | claimed |
| EP-0054390-B1 | DEHALOGENATION OF STEROIDS | THE UPJOHN COMPANY (US) | 1984-07-25 | — | — | EP | claimed |
| EP-0054390-A1 | Dehalogenation of steroids | THE UPJOHN COMPANY (US) | 1982-06-23 | — | — | EP | claimed |
| US-4325881-A | Debromination | THE UPJOHN COMPANY (US) | 1982-04-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376225-A1 | NOVEL COMPOUNDS OF 11BETA-HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION OR DEPLETION | CYP27A1, CYP27B1, TFAM | SMN1; SMN2 623/4885NR3C2 285/4885HSD11B2 152/4885 |
| US-20090053294-A1 | Anti Mineralocorticoid Therapy of Infection | NR3C2, HSPB1, HSP90AB2P | SMN1; SMN2 3817/4885NR3C2 1/4885HSD11B2 66/4885 |
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | NCOA1, NCOA2, NCOA3 | SMN1; SMN2 3109/4885NR3C2 9/4885HSD11B2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.